Key Developments: Danaher Corp (DHR.N)

DHR.N on New York Stock Exchange

86.27USD
19 Dec 2014
Price Change (% chg)

$0.27 (+0.31%)
Prev Close
$86.00
Open
$85.80
Day's High
$86.61
Day's Low
$85.68
Volume
2,111,336
Avg. Vol
712,836
52-wk High
$86.61
52-wk Low
$70.16

Search Stocks

Latest Key Developments (Source: Significant Developments)

Danaher Corp reaffirms Q4 2014 EPS outlook, gives FY 2015 EPS outlook above analysts' estimates
Thursday, 11 Dec 2014 06:00am EST 

Danaher Corp:Reaffirmed GAAP diluted net earnings per share guidance of $1.00 to $1.04 for Q4 2014.Expects FY 2015 adjusted diluted net earnings per share will be in the range of $4.35 to $4.45 which assumes core revenue growth of between 3 and 4 pct.Q4 2014 EPS of $1.02 - Thomson Reuters I/B/E/S.FY 2015 EPS of $4.01 - Thomson Reuters I/B/E/S.  Full Article

Danaher completes acquisition of Nobel Biocare
Thursday, 11 Dec 2014 01:00am EST 

Danaher Corp:Says it will settle the public tender offer for all the registered shares of Nobel Biocare Holding AG.Additional acceptance period for the tender offer expired on Dec. 4.Controls about 97pct of the issued registered shares of Nobel Biocare.  Full Article

Danaher announces quarterly dividend
Wednesday, 10 Dec 2014 08:00am EST 

Danaher Corp:Declares a regular quarterly dividend of $0.10 per share.Payable on Jan. 30, 2015 to holders of record on Dec. 26.  Full Article

GTCR completes sale of Devicor Medical Products to Danaher Corporation's Leica Biosystems
Thursday, 4 Dec 2014 09:27am EST 

GTCR:Has completed previously said sale of its portfolio company, Devicor Medical Products (Devicor or Co), to Danaher Corporation's Leica Biosystems.  Full Article

Danaher Corp's Leica Biosystems to acquire Devicor Medical Products Inc
Tuesday, 28 Oct 2014 06:58am EDT 

Danaher Corp:Says Leica Biosystems, part of company entered into a definitive agreement to acquire Devicor Medical Products Inc.Transaction is expected to close in early 2015.No other financial terms and conditions have been disclosed.  Full Article

Danaher Corp gives Q4 2014 outlook
Thursday, 16 Oct 2014 06:00am EDT 

Danaher Corp:Expects Q4 2014 GAAP diluted net earnings per share in the range of $1.00 to $1.04.Included in this range is about $125 million, or about $0.13 per diluted share, of anticipated productivity charges that are partially offset by about $0.07 per diluted share anticipated gain on the sale of marketable securities.  Full Article

Danaher Corp gives Q3 2014 outlook
Monday, 13 Oct 2014 06:45am EDT 

Danaher Corp:Expects Q3 2014 adjusted diluted net earnings per share of about $0.90.Expects Q3 2014 core revenue growth of about 3 pct.Q3 2014 EPS of $0.89, revenue of $4.895 bln - Thomson Reuters I/B/E/S.  Full Article

NetScout Systems Inc to acquire Danaher Corp's communications business
Monday, 13 Oct 2014 06:45am EDT 

NetScout Systems Inc:Has entered into a definitive agreement to acquire the Communications business of Danaher Corp, comprising Tektronix Communications, Arbor Networks, and certain parts of Fluke Networks.Under the terms of the transaction, Danaher shareholders will receive about 62.5 million shares of NetScout common stock, which values the transaction at $2.6 billion based on NetScout's closing price of $41.91 on Oct. 10.The transaction is expected to close in the first half of NetScout's fiscal year 2016.  Full Article

Danaher to buy Nobel Biocare Holding AG for $2.2 billion
Monday, 15 Sep 2014 01:00am EDT 

Danaher Corp:To acquire Nobel Biocare Holding AG for 17.10 Swiss franc per share.Says it the price represents total enterprise value of about $2.2 billion including debt assumed and net of cash acquired.Says offer prospectus is expected to be published on or around Oct. 1.  Full Article

Danaher announces quarterly dividend
Tuesday, 9 Sep 2014 04:00pm EDT 

Danaher Corporation:Approves a regular quarterly dividend of $0.10 per share payable on Oct. 31 to holders of record on Sept. 26.  Full Article

Nobel Biocare confirms guidance, profit beats estimates

ZURICH, Nov 6 - Swiss dental implant maker Nobel Biocare, which has agreed to be bought by U.S. healthcare company Danaher, confirmed its full-year sales and profitability targets on Thursday as it posted quarterly profit that beat expectations.

Search Stocks